fludarabine has been researched along with Nervous System Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (45.45) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Avivi, I; Bot, A; Bouabdallah, K; Dong, J; Dührsen, U; Houot, R; Kerber, A; Kersten, MJ; Kim, JJ; Kuruvilla, J; Lugtenburg, PJ; Minnema, MC; Plaks, V; Rossi, JM; Sherman, M; Song, KW; Thieblemont, C; Topp, MS; van Meerten, T; Vardhanabhuti, S; Wermke, M; Zheng, Y | 1 |
| Bund, C; De Seze, J; Kremer, S; Lhermitte, B; Namer, IJ | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Fabiano, AJ; Fenstermaker, RA; Qiu, J; Rigual, D | 1 |
| Avivi, I; Chakrabarti, S; Dogan, A; Goldstone, AH; Kottaridis, P; Kyriaku, C; Linch, D; Mackinnon, S; Milligan, DW | 1 |
| Cheson, BD; Foss, FM; Sorensen, JM; Vena, DA | 1 |
| Domizio, P; Fearnley, J; Gawler, J; Goldin, J; Johnson, PW; Lister, TA; Nagendran, K; Rohatiner, AZ | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Kemena, A; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, L | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Abonour, R; Kim, K; Longo, WL; Mosher, DF; Turman, NJ; Vidarsson, B; Wiersma, SR; Williams, EC; Woodson, RD | 1 |
| Adjei, AA; Dagnino, L; Paterson, AR; Wong, MM | 1 |
1 review(s) available for fludarabine and Nervous System Diseases
| Article | Year |
|---|---|
Neurotoxicity of purine analogs: a review.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Male; Middle Aged; Nervous System; Nervous System Diseases; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
4 trial(s) available for fludarabine and Nervous System Diseases
| Article | Year |
|---|---|
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Cyclophosphamide; Cytokine Release Syndrome; Drug Therapy, Combination; Female; Humans; Immunotherapy, Adoptive; Leukapheresis; Levetiracetam; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nervous System Diseases; Neutropenia; Propensity Score; Vidarabine; Young Adult | 2021 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Nervous System Diseases; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Virus Diseases | 2004 |
Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Gastrointestinal Diseases; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 1993 |
6 other study(ies) available for fludarabine and Nervous System Diseases
| Article | Year |
|---|---|
FDG PET and MRI Findings in a Case of Bing-Neel Syndrome.
Topics: Brain; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron Emission Tomography Computed Tomography; Vidarabine | 2018 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Brain Edema; Cerebellar Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Nervous System Diseases; Neurosurgical Procedures; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2013 |
Neurological illness following treatment with fludarabine.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Vidarabine | 1994 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Cytogenetic Analysis; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infections; Infusion Pumps; Leukemia; Lung Diseases; Male; Middle Aged; Nervous System Diseases; Prognosis; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Vidarabine | 2001 |
Protection against fludarabine neurotoxicity in leukemic mice by the nucleoside transport inhibitor nitrobenzylthioinosine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Hindlimb; Leukemia L1210; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Nervous System Diseases; Paralysis; Prodrugs; Thioinosine; Thionucleotides; Vidarabine | 1992 |